Abstract
This study assessed the safety and immunogenicity of a pediatric formulation of the 2003-2004 inactivated, trivalent, split virion influenza vaccine, administered in a 2-dose schedule in healthy children ages 6-36 months, of whom 94% had protective titers (> or =1/40) to at least 1 antigen. The 2003-2004 split virion influenza vaccine was safe and immunogenic in young children.
Publication types
-
Clinical Trial
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Viral / blood*
-
Child, Preschool
-
Humans
-
Immunization Schedule
-
Infant
-
Influenza A virus / immunology*
-
Influenza B virus / immunology*
-
Influenza Vaccines / administration & dosage
-
Influenza Vaccines / adverse effects*
-
Influenza Vaccines / immunology
-
Influenza, Human / prevention & control*
-
Treatment Outcome
-
Vaccination
-
Vaccines, Inactivated / administration & dosage
-
Vaccines, Inactivated / adverse effects*
-
Vaccines, Inactivated / immunology
-
Virion / immunology
Substances
-
Antibodies, Viral
-
Influenza Vaccines
-
Vaccines, Inactivated